Breakingviews on Twitter
Search League Tables

Tuesday, 31 May 2016

No need for Celesio to rush into $5 bln deal

The value of patience

Folding the German drug distributor into American rival McKesson would yield big savings. But Celesio has no CEO, is only in talks with McKesson and its controlling family is struggling and wants cash. Courting more buyers may bump up the price and put minority investors at ease.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.

Sign In

(Launches in a new window)